Earnings Releases·Nov 3, 2026, 4:00 PM ET

AtriCure — Third Quarter 2026 Earnings Summary

Worldwide revenue reached $154.5 million in Q3 2026, a 15.0% year-over-year increase, driven by strong U.S. growth of 17.1% and expanded gross margins to 77.3% from 75.5%.
Net income turned positive at $4.1 million per share ($0.08), reversing a $0.3 million loss in the prior year period, while Adjusted EBITDA surged 51% to $26.8 million.
Full-year 2026 guidance was raised to revenue of $606–$610 million, with Adjusted EBITDA projected at $91–$94 million and Adjusted EPS at $0.40–$0.46.
Strategic growth was fueled by pain management and appendage management franchises, though minimally invasive ablation sales declined due to physician adoption of PFA catheters.
The company maintains a strong balance sheet with $187.0 million in cash and $61.0 million in long-term debt, while the BoxX-NoAF clinical trial continues to progress.